An Open-label, Randomised, No-treatment-controlled, Single-centre, Phase I, Crossover Study Evaluating the Suppression of Plasma Cortisol from Symbicort budesonide/formoterol) pMDI 80/2.25 ?g, 8 Actuations bid, versus Symbicort Turbuhaler 160/4.5 ?g, 4 Inhalations bid, in Healthy Subjects
Study identifier:D5897C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-label, Randomised, No-treatment-controlled, Single-centre, Phase I, Crossover Study Evaluating the Suppression of Plasma Cortisol from Symbicort budesonide/formoterol) pMDI 80/2.25 ?g, 8 Actuations bid, versus Symbicort Turbuhaler 160/4.5 ?g, 4 Inhalations bid, in Healthy Subjects
Medical condition
asthma
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Dec 2007
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
